

APPLICATION NO.

09/582,842

United States Patent and Trademark Office

07/05/2000

12/16/2003

7590

WASHINGTON, DC 20037

2100 PENNSYLVANIA AVENUE NW

SUGHRUE MION ZINN MACPEAK & SEAS UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PAPER NUMBER

	www.aspro.go	
FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
KAZUYUKI SUGIYAMA	Q60017	2682
	EXAMINER	
	DO, PENSEE T	

1641

DATE MAILED: 12/16/2003

ART UNIT

Please find below and/or attached an Office communication concerning this application or proceeding.

		AII		
	Application No.	Applicant(s)		
	09/582,842	SUGIYAMA ET AL.		
Office Action Summary	Examiner	Art Unit		
	Pensee T. Do	1641		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status				
1) Responsive to communication(s) filed on <u>14 October 2003</u> .				
2a) This action is FINAL . 2b) ⊠ This	action is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims				
4)⊠ Claim(s) <u>1-3,6-12 and 24-30</u> is/are pending in the application.				
 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☒ Claim(s) <u>1-3, 6-12, 24-30</u> is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement. 				
Application Papers				
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.				
Priority under 35 U.S.C. §§ 119 and 120				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. a) The translation of the foreign language provisional application has been received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.				
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	5) 🔲 Notice of Informal I	r (PTO-413) Paper No(s) Patent Application (PTO-152)		
J.S. Patent and Trademark Office				

U.S. Patent and Trademark Office PTOL-326 (Rev. 11-03) Application/Control Number: 09/582,842

Art Unit: 1641

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

The request filed on October 14, 2002 for a Continued Examination (RCE) under 37 CFR 1.114 is acceptable and an RCE has been established. An action on the RCE follows.

Amendment Entry & Claim Status

The after-final amendment filed on August 11, 2003 has been acknowledged and entered.

Claims 1-3, 6-12, 24-30 are pending.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3, 6-12, 24-30 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The new limitation added to claims 1, 3, 6, 27, 30 that define the cross-linked avidin molecules raises new matter issue. Applicants admit that the specification fails to show clear support. Clear support for the new limitation must be present or disclosed in the specification.

Response to Arguments

Application/Control Number: 09/582,842

Art Unit: 1641

The arguments filed on August 11, 2003 have been fully considered but they are not found persuasive.

Applicants admit that support for the new limitation in claims 1, 3, 6, 27 and 30 is inherent in the specification since the specification teaches that avidin undergoes cross-linking before it is combined with the biotin molecules and the fact that the specification fails to discuss any cross-linking taking place other than between subunits of the avidin molecules, it is inherently supports the recitation of a biotin-avidin-biotin complex where only the avidin is cross-linked.

The specification must show clear support on such important limitation of the claimed invention. Such new limitation creates new matter issue if it is improperly supported.

Regarding the art rejections in the previous final office action, they are withdrawn in lieu of this new matter rejection. However, if the added limitation is removed to resolve the new matter issues, these art rejections would be re-applied to the present claims and the next office action would be made final.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Pensee T. Do whose telephone number is 703-308-4398. The examiner can normally be reached on Monday-Friday, 7:00-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 703-305-3399. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Pensee T. Do Patent Examiner December 9, 2003 CHRISTOPHER L. CHIN PRIMARY EXAMINER GROUP 1800-/641

Christoph L. Chi